Sharechat Logo

Spin fails to spark for Genesis after $9.6 million loss

Friday 1st February 2002

Text too small?
Wednesday's lacklustre result from biotechnology company Genesis Research & Development failed to spark much interest in sharemarket trading.

Genesis posted a $9.6 million loss, in line with its 2000 float forecast of $9.1 million. It presented a "bright side" by emphasising it had $47.9 million in cash, down from $61 million a year ago.

"All that demonstrates is that they've burned another $13 million of cash without generating any additional revenue," one analyst commented. Revenue fell $8.7 million to $20 million.

CEO Jim Watson said the company had reached agreement with the US Food and Drug Administration on the next phase of trials of its PVAC psoriasis vaccine.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MCY - Retirement of director
AIA - April 2025 Monthly traffic update
Sanford delivers an improved half year result
May 15th Morning Report
Devon Funds Morning Note - 14 May 2025
Winton Media Release - Ayrburn Film Hub
CEN - CONTACT ENERGY APPOINTS NEW CHIEF FINANCIAL OFFICER
VCT - Vector announces strategic review for its fibre business
May 14th Morning Report
Rua approves debt facility to accelerate sales.